GLP-1 Targeted Peptide Weight Loss Drugs Market Share, by Drug, 20242034 Figure 2: U.S
Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinsons disease: mechanisms of action
The supplier model is structured to minimize treatment disruption, supporting continuity across dosing phases and clinical milestones
If you are planning to conceive, actively trying to avoid pregnancy, or have concerns about potential side effects, discuss these with your provider
not recommended for use with DPP-4 inhibitors Common side effects : Gastrointestinal symptoms (nausea, vomiting, diarrhea) that typically diminish with continued use and proper dose titration Referral to endocrinology or obesity medicine specialists is appropriate for complex cases, including patients with multiple failed therapies, significant comorbidities, or those requiring comprehensive weight management programs
Importantly, in these and other clinical trials, the safety profile of GLP-1 receptor agonists was well established
